← sources

Latent Space: πŸ”¬Biology Is Turning Into Software β€” Matt McPartlon and Neil Patil, Chai Discovery

source: youtube (youtube:Latent Space)published 2026-08-11 20:48ingested 2026-08-12 07:12

retained text

Chai Discovery co-founder Matt McPartlon and product lead Neil Patil explain why pharma abruptly started buying AI design tools this year instead of forcing every AI-bio company to go build its own pipeline β€” and what specifically changed in the models to make drug design teams trust them. We trace the lineage from Chai-1, which they open-sourced for reasons that had almost nothing to do with the model itself, through the Chai-2 campaign that convinced Lilly, Pfizer, Novartis, and argenx to sign. Along the way: why their CEO says the company's real competitor is a mouse; the cryo-EM result so accurate the team's first reaction was to suspect the lab of sending back their own file; why the product looks more like SolidWorks than ChatGPT, and why Neil expects to throw most of it away; what happened when a pharma scientist saw results on a target she'd spent a decade on; why the compute market is quietly mispriced for this class of model; and the one bottleneck both guests would remove by fiat β€” which is not data, not compute, and not the models.

00:00:00 β€” What the product actually looks like
00:01:15 β€” Intros: Matt and Neil
00:03:22 β€” Four pharma partnerships
00:05:00 β€” The software-layer bet
00:07:00 β€” The 50-target challenge
00:08:12 β€” What is an antibody, and why target it
00:11:22 β€” ADCs, bispecifics, and pressing the switch
00:12:39 β€” How this was done before: mice and yeast display
00:14:29 β€” Selectivity and cross-reactivity
00:17:26 β€” Chai-1 and the MSA detour
00:19:41 β€” Sitting in the OpenAI offices
00:23:09 β€” Anatomy of a structure prediction model
00:25:49 β€” Chai-2: all-atom diffusion and crossing into design
00:28:21 β€” Co-designing sequence and structure
00:29:48 β€” How do you know a design is any good?
00:32:36 β€” Validation, cryo-EM, and the 0.33 Γ… result
00:35:26 β€” Chai-2.5, Chai-3, and betting on the models
00:39:18 β€” Building the product under pharma IP constraints
00:42:32 β€” Convincing scientists who hate AI tools
00:44:58 β€” The ten-year target
00:45:50 β€” Battle-testing without your own pipeline
00:47:40 β€” Waterfall to loop
00:49:04 β€” Levels of abstraction, and throwing the product away
00:52:06 β€” Epitope prediction: the harder problem
00:55:29 β€” The economics question
00:57:29 β€” Modalities you can't get from immunization
00:59:48 β€” What's really blocking science-to-engineering
01:01:51 β€” Buying compute is a terrible job
01:04:18 β€” Triangle attention and why GPUs hate it
01:05:28 β€” Durable execution and Temporal
01:08:27 β€” Complexity vs. the bitter lesson
01:09:37 β€” Inductive bias and data efficiency
01:15:13 β€” Will protein design get commoditized?
01:19:13 β€” No pipeline, no data moat?
01:21:13 β€” Per-partner fine-tuning
01:22:36 β€” Are all AI companies consulting companies?
01:23:42 β€” The highest-value token in any domain
01:24:20 β€” Pharma as VC: Genentech and Eroom's law
01:26:31 β€” Everyone is a capital allocator
01:29:23 β€” One bottleneck removed by fiat
01:32:07 β€” Takeaways

document fetched 2026-08-17 06:35 Β· canonical https://youtube.com/watch?v=Qp5xklyJySI